

Basic information	
<p>2023/2771(DEA) DEA - Delegated acts procedure</p> <p>Adjustment to the inflation rate of the amounts of the fees payable to the European Medicines Agency for the conduct of pharmacovigilance activities in respect of medicinal products for human use</p> <p>Supplementing 2013/0222(COD)</p> <p>Subject</p> <p>4.20.04 Pharmaceutical products and industry 8.40.08 Agencies and bodies of the EU</p>	Procedure completed - delegated act enters into force

Key players			
European Parliament	Committee responsible	Rapporteur	Appointed
	<div style="border: 1px solid red; display: inline-block; padding: 2px;">ENVI</div> Environment, Climate and Food Safety		

Key events			
Date	Event	Reference	Summary
29/06/2023	Non-legislative basic document published	C(2023)04261	
29/06/2023	Initial period for examining delegated act 2.0 month(s)		
12/07/2023	Committee referral announced in Parliament		
06/09/2023	Delegated act not objected by Parliament		

Technical information	
Procedure reference	2023/2771(DEA)
Procedure type	DEA - Delegated acts procedure
Procedure subtype	Examination of delegated act
	Supplementing 2013/0222(COD)
Stage reached in procedure	Procedure completed - delegated act enters into force
Committee dossier	ENVI/9/12404

Documentation gateway			
European Commission			
Document type	Reference	Date	Summary
Non-legislative basic document	C(2023)04261	29/06/2023	

Meetings with interest representatives published in line with the Rules of Procedure

Other Members

Name	Date	Interest representatives
FITZGERALD Frances	22/06/2023	Roche Products Ireland
FITZGERALD Frances	03/05/2023	Baxter Healthcare SA